GlassScriptPhysician profile
James L Tarala
NPI 1588819734
$1,529.37
in general payments reported to CMS, 2019-2025
25 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $240 · 2021: $462 · 2022: $198 · 2023: $195 · 2024: $59.82 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $272.85 | 2020-2025 | Ubrelvy |
| Astellas Pharma US INC | $259.36 | 2019-2023 | Myrbetriq, Veozah |
| Janssen Pharmaceuticals, INC | $168.25 | 2019-2024 | Xarelto |
| Amgen INC. | $78.80 | 2020-2022 | |
| Glaxosmithkline, LLC. | $75.83 | 2021-2023 | Shingrix, Pediarix, Menveo |
| Amarin Pharma, INC. | $70.56 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $62.21 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $54.22 | 2019-2021 | |
| Pfizer INC. | $53.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.51 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $42.99 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $41.56 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.86 | 2025 | Caplyta |
| Boston Scientific Corporation | $34.69 | 2025 | Watchman |
| Astrazeneca Pharmaceuticals LP | $32.81 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29.14 | 2020 | |
| Merck Sharp & Dohme LLC | $24.85 | 2021 | |
| Jazz Pharmaceuticals INC. | $22.55 | 2022 | |
| Abbott Laboratories | $21.50 | 2025 | Freestyle Libre 3 |
| Axonics, INC. | $19.12 | 2020 | |
| Phathom Pharmaceuticals, INC. | $18.40 | 2023 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $17.41 | 2020 | |
| Ibsa Pharma INC. | $14.58 | 2020 | |
| Corcept Therapeutics | $13.69 | 2023 | Korlym |
| Otsuka America Pharmaceutical, INC. | $13.47 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tarala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.